Compare Dollar General Corp. (DG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Inovio Pharmaceuticals Inc — how do they compare? Dollar General Corp. trades at $127.23 (market cap $27.42B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Dollar General Corp. is far larger — about 244.4× Inovio Pharmaceuticals Inc's market cap, and Dollar General Corp. pays a 1.9% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DG | INO | |
|---|---|---|
Market Cap | $27.42B | $112.19M |
Volume | 2,291,517 | 3,201,278 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $2.65 |
52-Week Low | $95.94 | $0.66 |
Typical Hold Time | 59 Days | 43 Days |
Enterprise Value | $41.60B | $83.51M |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $124.27, up 1.73% today, with a bullish technical signal from moving averages and strong analyst support (55.77% buy ratings). Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.48 exceeding the $2.01 estimate. The company benefits from tariff refunds boosting margins and is expanding delivery via Instacart and scaling its DG Media Network for growth.
The outlook is positive, with a consensus price target of $137.27 implying ~10% upside. Key opportunities include margin recovery initiatives and value-focused merchandising, but risks persist from consumer pressure and competitive discount retail dynamics. Net cash flow improved to $395 million in 2025, though profit margins have narrowed from 7.01% in 2022 to 2.77% in 2025.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
